Harvard Bioscience
HBIO
36 hedge funds and large institutions have $7.72M invested in Harvard Bioscience in 2026 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 17 reducing their positions, and 29 closing their positions.
918% more call options, than puts
Call options by funds: $112K | Put options by funds: $11K
31.54% more ownership
Funds ownership: 3.92% → 35.45% (+32%)
34% less capital invested
Capital invested by funds: $11.7M → $7.72M (-$3.95M)
41% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 17
43% less funds holding
Funds holding: 63 → 36 (-27)
90% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCNMGF
Nano-Cap New Millennium Growth Fund
Staten Island,
New York
|
+$321K |
| 2 |
CCM
Corsair Capital Management
New York
|
+$77.9K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$75.1K |
| 4 |
Two Sigma Investments
New York
|
+$72K |
| 5 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$47.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$274K |
| 2 |
Jane Street
New York
|
-$98.9K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$93.5K |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$93.1K |
| 5 |
Citigroup
New York
|
-$73.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GCA
51
Greenwood Capital Associates
Greenwood,
South Carolina
| – | -$18.6K | -2,775 | Closed |
|
|
AHL
52
Abel Hall LLC
Baton Rouge,
Louisiana
| – | -$16.9K | -2,528 | Closed |
|
|
TSS
53
Two Sigma Securities
New York
| – | -$11.7K | -1,755 | Closed |
|
54
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$11.4K | -1,703 | Closed |
|
|
VPIM
55
Vanguard Personalized Indexing Management
Oakland,
California
| – | -$11.1K | -1,654 | Closed |
|
56
Point72 Asset Management
Stamford,
Connecticut
| – | -$9.84K | -1,472 | Closed |
|
57
Simplex Trading
Chicago,
Illinois
| – | -$9.22K | -1,379 | Closed |
|
|
C
58
Certuity
North Palm Beach,
Florida
| – | -$9.15K | -1,368 | Closed |
|
|
GP
59
GSK plc
London,
| – | -$7.46K | -1,115 | Closed |
|
|
EI
60
Ethic Inc
New York
| – | -$7.32K | -1,094 | Closed |
|
|
BWP
61
Balboa Wealth Partners
Scottsdale,
Arizona
| – | -$6.69K | -1,000 | Closed |
|
62
Bank of America
Charlotte,
North Carolina
| – | -$301 | -45 | Closed |
|
63
Barclays
London,
United Kingdom
| – | -$14 | -2 | Closed |
|
64
Optiver Holding
Amsterdam,
Netherlands
| – | -$9 | -1 | Closed |
|
HBIO Hedge Fund Activity: Q1 2026 in Review
36 of the 8,133 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q1 2026, worth a combined $7.72M — down 34% from $11.7M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of HBIO and 3 opened new positions — a net loss of 26 holders — while 17 trimmed existing stakes and 10 added.
The largest buyer was Nano-Cap New Millennium Growth Fund, adding an estimated $321K. The largest seller was Portolan Capital Management, exiting entirely with an estimated $274K sold.
- 36 institutional investors held Harvard Bioscience (HBIO) as of Q1 2026, down from 63 in Q4 2025.
- Funds reported $7.72M of Harvard Bioscience stock for Q1 2026, down 34% quarter-over-quarter.
- 3 funds opened new Harvard Bioscience positions in Q1 2026 and 29 closed out, a net change of -26 holders.
- The largest Harvard Bioscience buyer in Q1 2026 was Nano-Cap New Millennium Growth Fund, an estimated $321K added.
- The largest Harvard Bioscience seller in Q1 2026 was Portolan Capital Management, an estimated $274K sold.
Based on aggregated 13F filings for Q1 2026.